Fintel reports that on November 18, 2024, Needham downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold.

“At Biogen Digital Health we have a full team dedicated to patient experience and user insights,” he said. “Their mission is to start from the need, improve the experience, and iterate.

Biopharma Leaders of Color (BLOC), a 501(c)(3) non-profit organization dedicated to promoting the professional advancement of people of color and growing the representation of leaders from ...

A SleepScore Labs scientific validation study revealed that Rebalance Health Systems delivers significant improvements in sleep, with research participants experiencing faster sleep onset, fewer ...

CareMessage, the largest patient activation platform in the United States for underserved populations, today announced the launch of their AI Assistant, adding ethical AI tools to their market-leading ...

Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio’s Chair of its ...

In a first-of-its-kind trial, physicians will review neurofilament test results with patients and decide whether to continue ...

A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, demonstrating significant improvement in ...

Also Read: Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial The results were shared at the American College of Rheumatology ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other genomics stocks. Genomics is the study of genes and how they function. Many rapidly growing ...

Needham forecasts Biogen revenues to remain stable until 2025, rising ~3% by 2026. Biogen will face ongoing challenges as expectations for Leqembi need to adjusted to more realistic levels.